Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Gaku Shimane

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7123-239X; OpenAlex author ID A5015453801. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 8

  1. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
  2. Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-12125-1↗
  3. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. Co-author DOI 10.1245/s10434-024-16851-z↗
  4. ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-16980-z↗
  5. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  6. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  7. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. First author DOI 10.3892/ol.2024.14272↗
  8. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 7 shared papers, 2023–2026 · strength 1.60
  2. Yohei Masugi · 6 shared papers, 2023–2026 · strength 1.18
  3. Yuko Kitagawa · 4 shared papers, 2024–2026 · strength 1.05
  4. Shutaro Hori · 5 shared papers, 2024–2026 · strength 1.05
  5. Yuta Abe · 5 shared papers, 2024–2026 · strength 1.05
  6. Yutaka Nakano · 4 shared papers, 2024–2026 · strength 0.82
  7. Masayuki Tanaka · 4 shared papers, 2024–2025 · strength 0.79
  8. Yuko Kitagawa · 2 shared papers, 2024–2025 · strength 0.42
  9. Yosuke Inoue · 2 shared papers, 2023–2025 · strength 0.42
  10. Atsushi Oba · 2 shared papers, 2023–2025 · strength 0.42
  11. Yu Takahashi · 2 shared papers, 2023–2025 · strength 0.42
  12. Sho Uemura · 2 shared papers, 2023–2026 · strength 0.39
  13. Hiroshi Nishihara · 2 shared papers, 2024 · strength 0.37
  14. Yoshihiro Ono · 1 shared paper, 2025 · strength 0.28
  15. Hiromichi Ito · 1 shared paper, 2025 · strength 0.28
  16. Yosuke Uematsu · 1 shared paper, 2026 · strength 0.26
  17. Koichi Aiura · 1 shared paper, 2024 · strength 0.19
  18. Yutaka Endo · 1 shared paper, 2024 · strength 0.19
  19. Yuki Hirose · 1 shared paper, 2023 · strength 0.13
  20. Kiyoshi Hasegawa · 1 shared paper, 2023 · strength 0.13
  21. Manabu Takamatsu · 1 shared paper, 2023 · strength 0.13
  22. Tsuyoshi Takeda · 1 shared paper, 2023 · strength 0.13
  23. Tatsunori Suzuki · 1 shared paper, 2023 · strength 0.13
  24. Tsuyoshi Hamada · 1 shared paper, 2023 · strength 0.13
  25. Michiie Sakamoto · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.